¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"complement binding reaction"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • chain initiation reaction
    ¿¬¼â°³½Ã¹ÝÀÀ
  • chain reaction
    ¿¬¼â¹ÝÀÀ
  • cholera red reaction
    ÄÝ·¹¶óÀû»ö¹ÝÀÀ
  • defensive reaction
    ¹æ¾îÀÛ¿ë
  • drug reaction
    ¾à¹°¹ÝÀÀ
  • dystonic reaction
    ±äÀåÀÌ»ó¹ÝÀÀ
  • delayed allergic reaction
    Áö¿¬¾Ë·¹¸£±â¹ÝÀÀ
  • delayed cell-mediated reaction
    Áö¿¬¼¼Æ÷¸Å°³¹ÝÀÀ
  • delayed hemolytic transfusion reaction
    Áö¿¬¿ëÇ÷¼º¼öÇ÷¹ÝÀÀ
  • delayed reaction
    Áö¿¬¹ÝÀÀ
  • depressive reaction
    ¿ì¿ï¹ÝÀÀ
  • dissociative reaction
    ÇØ¸®¹ÝÀÀ
  • donor reaction
    Á¦°øÀÚ¹ÝÀÀ, °ø¿©ÀÚ¹ÝÀÀ
  • dopa reaction
    µµÆÄ¹ÝÀÀ
  • downgrading reaction
    ÇÏÇâ¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • circular reaction
    ¼øÈ¯¹ÝÀÀ
  • color reaction
    ¹ß»ö¹ÝÀÀ, »öä¹ÝÀÀ
  • common reaction
    Á¤»ó¹ÝÀÀ
  • conglutination reaction
    ±³Âø¹ÝÀÀ
  • conjunctival reaction
    °á¸·¹ÝÀÀ
  • consensual pupillary reaction
    °ø°¨µ¿°ø¹ÝÀÀ
  • conversion reaction
    Àüȯ¹ÝÀÀ
  • counter reaction
    ¿ª¹ÝÀÀ
  • coupled reaction
    °ø¿ª¹ÝÀÀ, ¦Áø¹ÝÀÀ, ¿¬°á¹ÝÀÀ
  • cross reaction
    ±³Â÷¹ÝÀÀ
  • cutaneous reaction
    ÇǺιÝÀÀ
  • cutaneous drug reaction
    ÇǺξ๰¹ÝÀÀ
  • cytotoxic reaction
    µ¶¼º¹ÝÀÀ, ¼¼Æ÷µ¶¼º¹ÝÀÀ
  • reaction center
    (¢¡germinal center) Á¾ÀÚÁß½É, ¹èÁß½É
  • reaction time crossover
    ¹ÝÀÀ½Ã°£±³Â÷
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • graft versus host reaction (GVHR)
    ´ë¼÷ÁÖÀÌ½ÄÆí¹ÝÀÀ
  • grief reaction
    ¾Öµµ<ºñ¾Ö>¹ÝÀÀ(äîÓú<Ýèäî>Úãëë)
  • gross stress reaction
    ´ëÀÚ±Ø<ÃÑüÀû½ºÆ®·¹½º>¹ÝÀÀ(ÓÞí©Ð½<õÅô÷îÜ~>Úãëë)
  • group reaction
    Áý´Ü¹ÝÀÀ(̤ËÀËÑËô).
  • heat of reaction
    ¹ÝÀÀ¿­(Úãëëæð).
  • hemagglutination inhibition reaction
    ÀûÇ÷±¸ÀÀÁý¾ïÁ¦¹ÝÀÀ.
  • hemoclastic reaction
    Ç÷±¸ºØ±«¹ÝÀÀ.
  • hemolytic transfusion reaction
    ¿ëÇ÷¼º ¼öÇ÷¹ÝÀÀ.
  • heterogeneous reaction
    ºÒ±ÕÀϹÝÀÀ, ºÒ±ÕÁú¹ÝÀÀ.
  • heterophil(e) antibody reaction
    ÀÌÁ¾Ä£È­(¼º) Ç×ü¹ÝÀÀ(¡­Úãëë).
  • homograft reaction
    µ¿Á¾ÀÌ½ÄÆí¹ÝÀÀ.
  • hyperkinetic reaction
    °ú´Ù¿îµ¿ ¹ÝÀÀ
  • hypersensitive reaction
    °ú¹Î¼º ¹ÝÀÀ(ΦÚÂàõÚãëë).
  • hypersensitivity reaction
    °ú¹Î¹ÝÀÀ
  • hypnic reaction
    ¼ö¸é ¹ÝÀÀ(â²ØùÚãëë)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • complement system
    º¸Ã¼°è(¡­Í§)
  • complement system, alternative pathway
    ´ëü°æ·Î(ÓÛôðÌèÖØ)
  • complement system, classic pathway
    ÀüÇüÀû °æ·Î(îðúþîÜÌèÖØ)
  • complement typing
    º¸Ã¼Çüº°È­(úþܬûù)
  • complement unit
    º¸Ã¼´ÜÀ§(¡­Ó¤êÈ).
  • complement-mediated cytotoxicity
    º¸Ã¼ °ü·Ã¼º ¼¼Æ÷µ¶¼º(ÜÍô÷μ֤àõ á¬øàÔ¸àõ)
  • deficiency state, complement
    º¸Ã¼°áÇÌÁõ
  • dominant complement
    ¿ì¼ºº¸Ã¼(¡­ÜÍô÷).
  • endpiece of complement
    º¸Ã¼¸»Àý(ÜÍô÷ØÇï½).
  • gonococcal complement fixation test
    ÀÓ±Õº¸Ã¼°áÇÕ¹ÝÀÀ°Ë»ç.
  • heparin complement
    ÇìÆÄ¸°º¸Ã¼.
  • inactivation of complement
    º¸Ã¼ºñµ¿È­.
  • indirect complement fixation test
    °£Á¢º¸Ã¼°áÇÕ½ÃÇè
  • total hemolytic complement activity
  • treponema pallidum complement fixation test =tpcf
    Æ®·¹Æ÷³×¸¶º¸Ã¼°áÇÕ½ÃÇè
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • Folin reaction
    Æú¸° ¹ÝÀÀ(Úãëë)
  • formation reaction
    Çü¼º ¹ÝÀÀ(û¡à÷Úãëë)
  • formose reaction
    Æ÷¸£¸ð½º ¹ÝÀÀ(Úãëë)
  • fragmentation reaction
    Á¶°¢³»±â ¹ÝÀÀ(Úãëë)
  • fragment reaction
    Á¶°¢ ¹ÝÀÀ(Úãëë)
  • glyoxylic acid reaction
    ±Û¶óÀÌ¿Á½Ç»ê(ß«) ¹ÝÀÀ(Úãëë)
  • group transfer reaction
    ¿øÀÚ´Ü ÀüÀÌ ¹ÝÀÀ(ê«í­Ó¥ï®ì¹Úãëë)
  • half-reaction
    ¹Ý¹ÝÀÀ(ÚâÚãëë)
  • half-reaction time
    ¹Ý¹ÝÀÀ ½Ã°£(ÚâÚãëëãÁÊà)
  • Hill reaction
    Èú ¹ÝÀÀ(Úãëë)
  • Hopkins-Cole reaction
    ȩŲ½º-ÄÝ ¹ÝÀÀ(Úãëë)
  • idling reaction
    À¯ÇÑ ¹ÝÀÀ(ë´ùØÚãëë)
  • immune reaction
    ¸é¿ª ¹ÝÀÀ(Øóæ¹Úãëë)
  • irreversible reaction
    ºñ°¡¿ª ¹ÝÀÀ(ުʦæ½Úãëë)
  • Liebermann-Burchard reaction
    ¸®¹ö¸¸-¹öÄ«µå¹ÝÀÀ(Úãëë)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
TBI thyroid-binding index; thyroxine-binding index; tooth-brushing instruction; total-body irradiation; ...
TBP bithionol; testosterone-binding protein; thyroxine-binding protein; total bypass; tributyl phosphate...
C   1) Complement
  2) Centigrade; ¼·¾¾
CF   1) Cystic Fibrosis
  2) Complement Fixing antibody
  3) Conver...
CF test Complement Fixation test; º¸Ã¼°áÇÕ¹ý
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
C8 complement
C9 complement
C5a complement 5a
CML complement mediated lysis
CRP complement regulatory protein
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • nonspecific reaction
    ºñƯÀÌ ¹ÝÀÀ
  • order of reaction
    ¹ÝÀÀ Â÷¼ö
  • overanxious reaction
    °úºÒ¾È ¹ÝÀÀ
  • oxidase reaction
    »êÈ­ È¿¼Ò ¹ÝÀÀ
  • pain reaction
    µ¿Åë ¹ÝÀÀ
  • panic reaction
    °øÈ² ¹ÝÀÀ
    ±ØµµÀÇ ¶Ç´Â ºÒÇÕ¸®ÇÑ °øÆ÷¿Í ºÒ¾È µîÀÇ ¹ÝÀÀÀ» º¸ÀÌ´Â °Í.
  • periosteal reaction
    °ñ¸· ¹ÝÀÀ
  • peritectic reaction
    Æ÷Á¤ ¹ÝÀÀ
    ÇÕ±ÝÀ» ¿ëÀ¶ »óÅ¿¡¼­ ³Ã°¢ÇÒ ¶§, ÃÊÁ¤°ú ³ª¸ÓÁö ¾×»óÀÌ ¹ÝÀÀÇÏ¿© »õ·Î¿î °í»óÀ» Çü¼ºÇÏ´Â ¹ÝÀÀ.
  • photoallergic reaction
    ±¤¾Ë·¹¸£±â ¹ÝÀÀ
  • photodynamic reaction
    ±¤¿ªÇÐ ¹ÝÀÀ
  • polymerase chain reaction
    ÁßÇÕ È¿¼Ò ¿¬¼â ¹ÝÀÀ
  • potosensitivity reaction
    ±¤¼± °ú¹ÎÁõ ¹ÝÀÀ
  • psychogenic reaction
    ½ÉÀμº ¹ÝÀÀ
  • psychotic depressive reaction
    Á¤½Åº´Àû ¿ì¿ïÁõ, Á¤½Åº´¼º ¿ì¿ï ¹ÝÀÀ
  • reaction
    ¹ÝÀÀ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
octamer binding protein <protein> Transcription factor that binds to the octamer motif.
Examples: mammalian proteins Oct 1, Oct 2.
(18 Nov 1997)
odourant binding protein Proteins in nasal mucus that bind lipophilic odour-producing molecules and transfer them to the olfactory receptors. Similar proteins may mediate taste.
(05 Mar 2000)
testosterone-oestrogen-binding globulin A glycoprotein migrating as a beta-globulin. Its molecular weight, 52,000 or 95,000-115,000, indicates that it exists as a dimer. The protein binds testosterone, dihydrotestosterone, and estradiol in the plasma. Changes in its concentration significantly affect the ratio of unbound (biologically active) testosterone to estradiol in plasma.
(12 Dec 1998)
thyroid binding globulin <protein> Thyroid binding globulin (TBG) is a plasma protein which binds the majority of thyroid hormone in the bloodstream. Bound thyroid hormone is inactive, only the unbound fraction (0.3%) is considered active. Birth control pills and pregnancy can lead to increased TBG levels in the plasma. Androgens can decrease TBG levels in the plasma.
(27 Sep 1997)
thyroxine-binding globulin An alpha-globulin of blood with a strong binding affinity for thyroxine; triiodothyronine is bound to it much less firmly; a deficiency or excess of this protein may occur as a rare benign X-linked disorder.
Synonym: thyroxine-binding protein.
(05 Mar 2000)
thyroxine-binding protein An alpha-globulin of blood with a strong binding affinity for thyroxine; triiodothyronine is bound to it much less firmly; a deficiency or excess of this protein may occur as a rare benign X-linked disorder.
Synonym: thyroxine-binding protein.
(05 Mar 2000)
thyroxine-binding proteins A group of proteins that includes thyroxine-binding globulin, a glycoprotein that serves as the major and specific carrier of thyroxine in plasma, accounting for 70-75% of the bound thyroxine; thyroxine-binding prealbumin, an albumin that serves as the secondary carrier, accounting for between 20 and 25% of the bound thyroxine; and serum albumin, which accounts for the remaining bound thyroxine.
(12 Dec 1998)
total iron binding capacity <biochemistry, haematology> A test that measures indirectly the transferrin level in the bloodstream.
Transferrin is a protein that carries iron in the body. Normal values are 240 to 450 mcg/dl. This test is used to evaluate anaemia. Greater than normal total iron binding capacity can be seen in: iron deficiency anaemia, late pregnancy and polycythaemia vera.
Lower than normal total iron binding capacity can be seen in cirrhosis, sickle cell anaemia, hypoproteinaemia, pernicious anaemia and haemolytic anaemia. The use of birth control pills can lead to increased total iron binding capacity measurements.
Acronym: TIBC
(12 Jan 1998)
fatty acid binding protein A fatty acid-binding protein that participates in the intracellular movement of fatty acids.
Synonym: fatty acid binding protein.
(05 Mar 2000)
fatty acid binding proteins <biochemistry> Group of small cytosolic proteins that bind fatty acids or other organic solutes.
(18 Nov 1997)
zero time-binding DNA DNA that has become the duplex form at the start of a reassociation process.
Acronym: DNA
(05 Mar 2000)
ligand binding site The site on a protein's surface that binds a ligand; equivalent to the active site if the ligand is the substrate of an enzyme.
(05 Mar 2000)
accelerated reaction A response occurring in a shorter time than expected; the cutaneous manifestations occurring during the period between the second and tenth day following smallpox vaccination; because it is intermediate between a primary reaction and an immediate reaction, it is regarded as evidence of some degree of resistance.
Synonym: vaccinoid reaction.
(05 Mar 2000)
acid reaction Any test by which an acid reaction is recognised such as the change of blue litmus paper to red, an excess of hydrogen ions over hydroxide ions in aqueous solution indicated by a pH value less than 7 (at 22°C).
Compare: dissociation constant of water.
(05 Mar 2000)
acute-phase reaction <immunology, rheumatology> Refers to the changes in synthesis of certain proteins within the serum during an inflammatory response, which provides rapid protection for the host against microorganisms via non-specific defense mechanisms.
It consists of fever, an increase in inflammatory humoral factors, and an increased synthesis by hepatocytes of a number of proteins or glycoproteins usually found in the plasma; the reaction is mediated by endogenous pyrogens, the hypothalamus, adrenal hormones, and other factors.
(12 Jul 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
ÅëÇÕ°Ë»ö ¿Ï·á